Drug-Eluting Stents: Safe But Not Sufficient

作者：Vogel Robert A^*

来源：JACC: Cardiovascular Interventions , 2009, 2(6): 513-514.

DOI：10.1016/j.jcin.2009.04.002

• angioplasty
• coronary artery disease
• stent

Drug-eluting stents (DES) were quickly adopted into clinical practice after they were demonstrated to reduce restenosis and repeat target lesion revascularization (TLR) compared with bare-metal stents (BMS) (1,2). Concern soon surfaced over reports of late stent thrombosis with DES (3), leading to the release of 2 Federal Drug Agency advisories in 2006. Protracted dual antiplatelet therapy is now advised after DES implantation. Differences in antiplatelet therapy given to patients receiving DES and BMS complicate the interpretation of the relative long-term benefit of stent type. We are now nearing the end of the DES versus BMS debate, with recent studies documenting the safety of current DES (4). Our major concern should now shift back to the underlying problem beyond the target lesion, namely progressive coronary atherosclerosis.

• 出版日期2009-6